Search clinical trials for: Xarelto (Rivaroxaban)

Total 489 results

Bayer
Janssen Research & Development, LLC

Not yet recruiting

An Observational Study to Learn More About How Safe Rivaroxaban is And How Well it Works in Children With Congenital Heart Disease Who Had a Heart Surgery Called the Fontan Procedure

Children | Congenital Heart Disease | Prevention of Venous Thromboembolism | Fontan Procedure

Japan
Bayer
Janssen Research & Development, LLC

Completed

Study to Gain Information on the Drug Xarelto for the Prevention of Brain Attack and Blockage of an Artery in the Non-central Nervous System Due to Irregular Heartbeat in Taiwanese Patients Suffering From Decreased Renal Function (XARETO)

Non-valvular Atrial Fibrillation (NVAF)

Taiwan
Bayer
Janssen Research & Development, LLC

Completed

Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban (EMIR)

Atrial Fibrillation

Spain
Bayer
Janssen Research & Development, LLC

Completed

Xarelto [SPAF] Post-marketing Surveillance in Japan

Brain Ischemia

Japan
Bayer
Janssen Research & Development, LLC

Completed

Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment-naïve Asian Patients With Non-valvular Atrial Fibrillation (XaMINA)

Atrial Fibrillation

Korea, Republic of, Taiwan
Bayer
Janssen Research & Development, LLC

Completed

Satisfaction/Quality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) Indication (SATORI)

Venous Thrombosis

France
Bayer
Janssen Scientific Affairs, LLC

Completed

Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism (BOX-AF)

Atrial Fibrillation

Belgium
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer

Venous Thrombosis | Deep Vein Thrombosis

Italy, Austria, Brazil, Hungary, Netherlands, South Africa, Israel, Australia, Germany
The George Institute
Bayer; King Abdullah International Medical Research Center; George Clinical Pty... and other collaborators

Recruiting

Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK)

Cardiovascular Disease | Chronic Kidney Diseases | Dialysis-dependent Kidney Failure

Taiwan, Australia, Malaysia, Tunisia, Singapore, Canada, France, India, Saudi Arabia
Bayer

Completed

BAY59-7939 in Atrial Fibrillation Once Daily (OD)

Atrial Fibrillation

Japan
Insel Gruppe AG, University Hospital Bern

Completed

Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial (ELAN)

Ischaemic Stroke

Belgium, Ireland, Israel, Germany, India, United Kingdom, Austria, Switzerland, Finland, Norway, Italy, Portugal, Slovakia, Japan, Greece
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for Real Life Anticoagulation in Pulmonary Embolism (PE) in China (XAPEC)

Pulmonary Embolism

China
Bayer
Janssen Research & Development, LLC

Completed

Xarelto Evidence in Real Life of Patients' Preference and Satisfaction Study (X-PRESS)

Atrial Fibrillation

Taiwan
Bayer

Withdrawn

Study to Observe Safety of Xarelto in VTE Prophlylaxis After Elective TKR (Total Knee Replacement) or THR (Total Hip Replacement) (XYRIS)

Total Hip Replacement | Total Knee Replacement | Prophylaxis, Thromboembolism, Venous
Bayer
Janssen Research & Development, LLC

Completed

Oral Rivaroxaban in Children With Venous Thrombosis (EINSTEINJunior)

Venous Thrombosis

France, United States, Switzerland, Netherlands, Canada, Germany, Austria, Australia, Israel, Italy
Bayer
Janssen Research & Development, LLC

Completed

Study to Gather Information on the Kidney Function of Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) Treated With Rivaroxaban or Vitamin K Antagonists (ANTENNA)

Non-Valvular Atrial Fibrillation

United Kingdom
Bayer
Janssen Research & Development, LLC

Completed

An Observational Study Called H2H-OSCAR-US to Learn More About How Well Rivaroxaban Works and How Safe it is Compared to Apixaban Under Real World Conditions in People in the US With Cancer Who Have Problems Due to Formation of Blood Clots in the Veins (Venous Thromboembolism) (H2H-OSCAR-US)

Cancer | Venous Thromboembolism | Treatment of Venous Thromboembolism in Cancer Patients

Germany
Bayer

Completed

BAY59-7939 Japanese in Atrial Fibrillation (2nd)

Atrial Fibrillation

Japan
Seoul National University Hospital
Seoul National University Bundang Hospital; Daegu Catholic University Medical... and other collaborators

Unknown

Prevention of Recurrence After Thrombolysis in Acute Iliofemoral Venous Thrombosis (PRAIS) Study (PRAIS)

Ileofemoral Deep Vein Thrombosis

Korea, Republic of
Kevin H.M. Kuo, MD, MSc, FRCPC

Recruiting

THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS) (THIS)

Sickle Cell Disease | Venous Thromboembolism | Central Venous Catheter Thrombosis

Canada
Ottawa Hospital Research Institute
University of Alberta; Hamilton Health Sciences Corporation; Queen Elizabeth...

Completed

Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines (TRIM-Line)

Cancer | Central Venous Catheter Thrombosis | Upper Extremity Deep Vein Thrombosis

Canada
Insel Gruppe AG, University Hospital Bern
Bayer; Janssen Pharmaceuticals

Completed

Rivaroxaban as Thrombosis Prophylaxis in Bariatric Surgery (BARIVA)

Bariatric Surgery

Switzerland
Bayer
Janssen Research & Development, LLC

Completed

A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and Diabetes (RIVA-DM)

Atrial Fibrillation

United States
Bayer
Janssen Research & Development, LLC; Colorado Prevention Center

Completed

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities (VOYAGER PAD)

Peripheral Artery Disease

Poland, Belgium, France, Spain, China, Korea, Republic of, United States, Switzerland, Estonia, Portugal, Japan, Hungary, Canada, Netherlands, Finland, Austria, United Kingdom, Germany, Czechia, Thailand, Brazil, Denmark, Italy, Russian... and more
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients (MAGELLAN)

Venous Thromboembolism

Belgium, France, Norway, Spain, China, Taiwan, United States, Switzerland, Colombia, Canada, Estonia, New Zealand, Finland, Italy, Portugal, Japan, Singapore, Germany, Greece, Australia, Sweden, Austria, Chile, Slovakia, United Kingdom, M... and more
Bayer
Janssen Pharmaceutical Companies (formerly Johnson & Johnson Pharmaceutical...

Recruiting

An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolism

Venous Thromboembolism

Japan
The Young Investigator Group of Cardiovascular...

Completed

Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi (No-LVT)

Left Ventricular Thrombosis | Anticoagulants; Increased

Egypt
Bayer
Janssen Scientific Affairs, LLC

Completed

Use of Direct Oral Anticoagulants in UK

Stroke

United Kingdom
Bayer

Completed

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement. (RECORD 4)

Venous Thromboembolism

Poland, United States, India, Denmark, Canada, Sweden, Bulgaria, Israel, Lithuania, Norway, Pakistan, Mexico, Sri Lanka
Bayer
Janssen, LP

Completed

Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) (REATTAIN)

Atrial Fibrillation

Sweden
Bayer
Janssen Research & Development, LLC

Completed

Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet

Biological Availability

Germany
Bayer
Janssen Research & Development, LLC

Completed

A Study to Gather Information About Rivaroxaban in Patients in the United Kingdom Who Have Cancer and Thrombosis (OSCAR-UK)

Treatment of Venous Thromboembolism in Cancer Patients

United Kingdom
Janssen Research & Development, LLC
Bayer

Completed

A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis

End-Stage Renal Disease

United States
Bayer
Janssen Research & Development, LLC

Not yet recruiting

A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE) (XAPAEDUS)

Venous Thromboembolism | Children Under 2 Years

Spain, Sweden, Denmark, France
Bayer

Completed

Study to Compare the Effectiveness of Rivaroxaban (Xarelto) Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism in Routine Clinical Practice in Germany

Venous Thromboembolism

Germany
Bayer
Janssen Research & Development, LLC

Completed

EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis (EINSTEIN Jr)

Venous Thromboembolism

Belgium, China, Hong Kong, United States, Switzerland, Spain, Russian Federation, Singapore, Canada, Germany, Netherlands, United Kingdom, Austria, Brazil, Israel, Italy, Mexico, Turkey, France, Australia, Finland, Hungary, Japan, Arg... and more
Hanoi Medical University
Bach Mai Hospital

Unknown

Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Using Propensity Score Matching

Thrombosis | Deep Vein Thrombosis | Surgery--Complications

Vietnam
Bayer

Completed

Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement (ODIXa-HIP2)

Venous Thromboembolism

Italy, Spain, Denmark, Netherlands, Belgium, Austria, Germany, Poland, Sweden, Israel, France, Norway, United Kingdom
Bayer
Janssen Scientific Affairs, LLC

Completed

Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan

Non-valvular Atrial Fibrillation (NVAF)

Japan
Bayer
Janssen Research & Development, LLC

Completed

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon (ReLoaDeD)

Atrial Fibrillation

Germany
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty (XAMOS)

Venous Thromboembolism

Switzerland, China, Slovakia, France, Germany, Hungary, Korea, Republic of, Singapore, South Africa, Spain, Sweden, Philippines, Australia, Austria, Colombia, Czech Republic, Estonia, Hong Kong, Italy, Latvia, Lebanon, Lithuania, Macedonia... and more
Bayer
Janssen Research & Development, LLC

Completed

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy (XALIA)

Venous Thrombosis | Deep Vein Thrombosis

Switzerland, France, Germany, Hungary, Spain, Sweden, Austria, Czech Republic, Italy, Moldova, Republic of, Slovenia, Ukraine, United Kingdom, Israel, Portugal, Belgium, Denmark, Greece, Netherlands, Canada, Norway
Bayer

Completed

Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement (ODIXaHIP-OD)

Venous Thromboembolism

Italy, Spain, Denmark, Netherlands, Belgium, Austria, Germany, Poland, Sweden, Israel, Norway, United Kingdom, France
Bayer
Janssen Research & Development, LLC

Completed

Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction (CALLIPER)

Atrial Fibrillation

United States
Bayer
Janssen Research & Development, LLC

Completed

Relative Bioavailability Study in Healthy Subjects Comparing 2 Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions

Pharmacokinetics

Germany
Bayer
Janssen Scientific Affairs, LLC

Completed

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Venous Thrombosis | Atrial Fibrillation | Acute Coronary Syndrome | Pulmonary Embolism

Netherlands
Susan Smyth
Janssen Scientific Affairs, LLC

Terminated

XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis (XENITH)

Venous Thrombosis | Pulmonary Embolism
Bayer
Janssen Research & Development, LLC

Completed

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists

Atrial Fibrillation

Germany
Bayer
Janssen Research & Development, LLC

Completed

BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies

Atrial Fibrillation

Germany
Bayer
Janssen Research & Development, LLC

Completed

Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy (XALIA LEA)

Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE)

Turkey, Russian Federation, Korea, Republic of, Mexico, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Egypt, Kazakhstan, Algeria, Lebanon, Saudi Arabia, Ukraine, Jordan, Kenya, Kuwait, Morocco, Qatar, United Arab Emirates

Search clinical trials for: Xarelto (Rivaroxaban)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations